Brief: Nicox Granted New Patent For NCX 470 In China

Nicox SA

21/02/2022 06:42

Feb 21 (Reuters) - Nicox SA  NCOX.PA :
    * GRANTED NEW PATENT FOR NCX 470 IN CHINA, EXTENDING
COVERAGE TO
2039
    * NCX 470 IS CURRENTLY BEING EVALUATED AGAINST LATANOPROST,
THE
LEADING PROSTAGLANDIN ANALOG BY PRESCRIPTION VOLUME IN THE U.S.,
IN THE ONGOING MONT BLANC AND DENALI PHASE 3 CLINICAL TRIALS,
WITH RESULTS EXPECTED IN Q1 2023 AND BY THE END OF 2023,
RESPECTIVELY
    * HAS LICENSED EXCLUSIVE RIGHTS TO OCUMENSION FOR NCX 470 IN
CHINA, KOREA AND SOUTHEAST ASIA
    * OCUMENSION HAS PAID €18 MILLION TO NICOX FOR RIGHTS IN
CHINA,
KOREA AND SOUTHEAST ASIA
    * STANDS TO RECEIVE TIERED ROYALTIES OF BETWEEN 6% AND 12%
ON
SALES OF NCX 470 BY OCUMENSION

Source text for Eikon:  ID:nGNE21VP7v 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))